Issued on: 15/04/2026 - 14:53
Revolution Medicines' experimental oral drug helped patients with pancreatic cancer live longer and showed an improvement in survival without worsening of the disease in a keenly anticipated late-stage trial. Patients who received the once-daily pill, daraxonrasib, showed a median overall survival of 13.2 months compared with 6.7 months for those who were given intravenous cytotoxic chemotherapy, the standard of care, the company said on Monday.
Protesters seeking India election chief's ouster detained, as 'cockroach' leaders released
Saudi-led coalition says new attack at Riyadh airport causes fire, day after strike kills 12
Trump's energy ceasefire announcement was 'news for me' (Zelensky)
Pope Leo says he will undergo surgery for small growth on lung
France: Can the left unite behind a single candidate?
India's 'cockroach' leaders vow to keep up election protests
Strike on Riyadh: What options for the Saudi-led coalition?
Strike on Riyadh: Trump signals US could join action against Houthis
Trump says Ukraine needs new president who will agree to end war
Spain: Sánchez and Feijóo launch campaigns
The content you requested does not exist or is not available anymore.
